PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, 30 August 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Bank of America Corporation on 25 August 2017.

Bank of America Corporation (taking into account the holdings of its subsidiary undertakings) notified Ablynx that it has exceeded the 5% threshold as of 18 August 2017 and now holds a total of 3,159,205 shares with voting rights, representing 5.16% of the current 61,169,732 outstanding Ablynx shares (versus 4.97% notified previously on 5 July 2017).

The notified details are presented below:

* Merrill Lynch Professional Clearing Corporation and Merrill Lynch Pierce, Fenner & Smith Incorporated are controlled by Bank of America Corporation. Bank of America Corporation is not a controlled entity.

** Type of financial instrument: "Right of Use" that represents a right of rehypothecation (not yet exercised) that Merrill Lynch Professional Clearing Corporation has over stock held on behalf of Prime Brokerage clients. The underlying shares are common stock. The company holds the shares as a Prime Broker on behalf of the underlying Prime Brokerage clients. The shares are held in an omnibus account. Since Merrill Lynch Professional Clearing Corporation has the right of use over the shares although this entity does not have legal or beneficial ownership, the shares are included as a Financial Instrument holding.

Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  [email protected]

Lies Vanneste
Director Investor Relations
t:   +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e:  [email protected]

Follow us on Twitter @AblynxABLX

Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: [email protected]

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/3b2d7cb9-194d-45a0-ad9f-736af1727964